Accure Therapeutics presented at EAN the improvement of neurodegeneration with ACT-02 in a preclinical study of Parkinson’s disease
Accure Therapeutics presented at ECTRIMS four communications reporting the progress of ACT-01 neuroprotective therapy for Multiple Sclerosis
New targets and therapeutics for neuroprotection, remyelination and repair in multiple sclerosis
